Transcriptome profiling analysis reveals that CXCL2 is involved in anlotinib resistance in human lung cancer cells

[1]  B. Han,et al.  Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for nonsmall cell lung cancer therapy , 2018, European Respiratory Journal.

[2]  Ying Cheng,et al.  Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial , 2018, JAMA oncology.

[3]  B. Han,et al.  Liquid Biopsy Promotes Non-Small Cell Lung Cancer Precision Therapy , 2018, Technology in cancer research & treatment.

[4]  Xiaodong Zhao,et al.  Jinfukang induces cellular apoptosis through activation of Fas and DR4 in A549 cells , 2018, Oncology letters.

[5]  Ryohei Katayama,et al.  Identification of Mutation Accumulation as Resistance Mechanism Emerging in First‐Line Osimertinib Treatment , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[6]  Laising Yen,et al.  The role of HGF-MET pathway and CCDC66 cirRNA expression in EGFR resistance and epithelial-to-mesenchymal transition of lung adenocarcinoma cells , 2018, Journal of Hematology & Oncology.

[7]  N. Lu,et al.  Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1. , 2018, Gene.

[8]  M. Zheng,et al.  Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor‐2 inhibitor , 2018, Cancer science.

[9]  Ying Cheng,et al.  Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302) , 2018, British Journal of Cancer.

[10]  B. Han,et al.  Efficacy and safety of third-line treatment with anlotinib in patients with refractory advanced non-small-cell lung cancer (ALTER-0303): a randomised, double-blind, placebo-controlled phase 3 study , 2017 .

[11]  D. Figeys,et al.  An autocrine inflammatory forward-feedback loop after chemotherapy withdrawal facilitates the repopulation of drug-resistant breast cancer cells , 2017, Cell Death & Disease.

[12]  P. Tassone,et al.  A phase II, noncomparative, open label, multicentre, study of AZD9291 in patients with locally advanced or metastatic EGFR mutated “T790M undetectable or unknown” non-small cell lung cancer (stage IIIB-IV) after no immediate prior EGFR TKI (OSIRIS study). , 2017 .

[13]  A. Nielsen,et al.  MET amplification and epithelial-to-mesenchymal transition exist as parallel resistance mechanisms in erlotinib-resistant, EGFR-mutated, NSCLC HCC827 cells , 2017, Oncogenesis.

[14]  Steven E. Schild,et al.  Non-small cell lung cancer, version 5.2017: Clinical practice guidelines in oncology , 2017 .

[15]  Yukyung Jun,et al.  Rapid emergence and mechanisms of resistance by U87 glioblastoma cells to doxorubicin in an in vitro tumor microfluidic ecology , 2016, Proceedings of the National Academy of Sciences.

[16]  F. Du,et al.  Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors , 2016, Journal of Hematology & Oncology.

[17]  M. Cheng,et al.  Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. , 2016, Toxicology letters.

[18]  Chee-Hong Wong,et al.  Integrative epigenomic analysis reveals unique epigenetic signatures involved in unipotency of mouse female germline stem cells , 2016, Genome Biology.

[19]  A. Abad,et al.  Curcumin mediates oxaliplatin-acquired resistance reversion in colorectal cancer cell lines through modulation of CXC-Chemokine/NF-κB signalling pathway , 2016, Scientific Reports.

[20]  J. Ahn,et al.  AZD9291 overcomes T790 M-mediated resistance through degradation of EGFRL858R/T790M in non-small cell lung cancer cells , 2016, Investigational New Drugs.

[21]  Xiaodong Zhao,et al.  Epigenetic Profiling of H3K4Me3 Reveals Herbal Medicine Jinfukang-Induced Epigenetic Alteration Is Involved in Anti-Lung Cancer Activity , 2016, Evidence-based complementary and alternative medicine : eCAM.

[22]  D. Ettinger,et al.  NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016. , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

[23]  Yong Wang,et al.  Loss of miR-532-5p in vitro promotes cell proliferation and metastasis by influencing CXCL2 expression in HCC. , 2015, American journal of translational research.

[24]  Xin-yang Wang,et al.  CXCL5/CXCR2 axis promotes bladder cancer cell migration and invasion by activating PI3K/AKT-induced upregulation of MMP2/MMP9. , 2015, International journal of oncology.

[25]  W. Pao,et al.  Acquired resistance to TKIs in solid tumours: learning from lung cancer , 2014, Nature Reviews Clinical Oncology.

[26]  Steven J. M. Jones,et al.  Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.

[27]  Andreas Rimner,et al.  Erlotinib versus radiation therapy for brain metastases in patients with EGFR-mutant lung adenocarcinoma. , 2014, International journal of radiation oncology, biology, physics.

[28]  Q. Hamid,et al.  Differential Roles of CXCL2 and CXCL3 and Their Receptors in Regulating Normal and Asthmatic Airway Smooth Muscle Cell Migration , 2013, The Journal of Immunology.

[29]  Anushya Muruganujan,et al.  Large-scale gene function analysis with the PANTHER classification system , 2013, Nature Protocols.

[30]  David R. Kelley,et al.  Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks , 2012, Nature Protocols.

[31]  T. Mok,et al.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.

[32]  K K Jain,et al.  Recent Advances in Nanooncology , 2008, Technology in cancer research & treatment.

[33]  Joon-Oh Park,et al.  MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.

[34]  Jin-Yuan Shih,et al.  EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer. , 2005, The New England journal of medicine.

[35]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[36]  Brad T. Sherman,et al.  DAVID: Database for Annotation, Visualization, and Integrated Discovery , 2003, Genome Biology.

[37]  A. Jemal,et al.  Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.

[38]  Renato Martins,et al.  Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

[39]  M. Denis,et al.  Rapid clearance of circulating tumor DNA during treatment with AZD9291 of a lung cancer patient presenting the resistance EGFR T790M mutation. , 2016, Lung cancer.

[40]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[41]  Brad T. Sherman,et al.  DAVID: Database for Annotation, Visualization, and Integrated Discovery , 2003, Genome Biology.